Replimune Reports Widening Losses, Short Cash Runway, and Going Concern Warning
REPL has more than doubled off its 52-week low of $1.5.
Summary
Replimune reported widening losses and a going concern warning, with cash only until Q1 2027, following a 55% workforce reduction and ongoing FDA review for its lead drug candidate.
Key Events · Earnings and Guidance · REPL
-
Going Concern Warning Issued
The company explicitly stated that there is substantial doubt about its ability to continue as a going concern, with existing cash and investments projected to fund operations only into the first calendar quarter of 2027.
-
Net Loss Widens Significantly
Replimune reported a net loss of $313.9 million for the fiscal year ended March 31, 2026, an increase from $247.3 million in the prior year, bringing the accumulated deficit to $1.26 billion.
-
Major Workforce Reduction Implemented
Following the FDA's second Complete Response Letter for RP1 in April 2026, the company implemented a restructuring plan that included a reduction of its workforce by approximately 55%.
-
FDA Review for RP1 Ongoing
The FDA accepted the Biologics License Application (BLA) resubmission for RP1 in advanced melanoma, setting an action date of August 2, 2026, and planning an advisory committee meeting in late July 2026.
Analysis · REPL · Life Sciences
Replimune Group's annual report reveals a significant deterioration in its financial health, with a net loss of $313.9 million for fiscal year 2026 and an accumulated deficit exceeding $1.2 billion. The company explicitly states substantial doubt about its ability to continue as a going concern, projecting its cash and investments will only fund operations into the first quarter of 2027. This financial distress follows the FDA's second Complete Response Letter for its lead drug candidate RP1, which led to a drastic 55% workforce reduction in April 2026. While the FDA has accepted the RP1 BLA resubmission with an action date of August 2, 2026, and an advisory committee meeting in late July, the company's immediate future hinges on this approval and its ability to secure additional financing.
At the time of this filing, REPL was trading at $11.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $960.3M. The 52-week trading range was $1.50 to $13.24. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.